| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 2, 2026, it was agreed that the employment of Kieran O’Kane, Chief Commercial Officer of Biodesix, Inc. (the “Company”) would end effective November 2, 2026 (the “Separation Date”). Mr. O’Kane will be eligible for separation ... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Delivered total revenue of $24.0 million, an increase of 10% year over year |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; |
| 20 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Biodesix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) on May 19, 2026. At the Annual Meeting, the Company’s stockholders voted on: (i) the election of two Class III director nominees to serve ... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Delivered 41% revenue growth and 83% gross margin in Q4 2025; |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; |
| 01 Oct 2025 |
8-K: Other Events
On September 26, 2025, Biodesix, Inc., a Delaware corporation (the “Company”) received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compli... |
| 15 Sep 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Biodesix, Inc., a Delaware corporation (the “Corporation”), does hereby certify as follows: |
| 11 Sep 2025 |
8-K: Other Events
Louisville, CO September 11, 2025 — Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s comm... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; |
| 21 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Biodesix, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) on May 20, 2025. At the Annual Meeting, the Company’s stockholders voted on: (i) the election of two Class II director nominees to serve u... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; |
| 17 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 28 Mar 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On March 24, 2025, Biodesix, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days... |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; |
| 10 Jan 2025 |
8-K: Results of Operations and Financial Condition
Grew full-year revenue to an estimated $71.3 million, an increase of 45% |
| 01 Nov 2024 |
8-K: Results of Operations and Financial Condition
Biodesix Announces Third Quarter 2024 Results and Highlights |
| 15 Aug 2024 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Corporate Presentation Biodesix is a blood-based lung diagnostic company addressing a large unmet need with limited competition © 2024 Biodesix, Inc. All rights reserved. 1 3Q24 |
| 07 Aug 2024 |
8-K: Results of Operations and Financial Condition
Biodesix Announces Second Quarter 2024 Results and Highlights |
Loading...